Epicutis is thrilled to announce that it has successfully raised $10,000,000 in funding, marking a pivotal moment in the future of science-based luxury skincare. This exciting investment not only underscores the market’s confidence in Epicutis’ commitment to treating skin health rather than simply aging but also bolsters the company’s mission of promoting clean beauty with fewer ingredients. Epicutis has earned its reputation as a leader in innovative skincare by leveraging patented active ingredients in small-batch formulations developed under the expert guidance of formulator Masanori Tamura. This decisive funding will allow the company to further enhance its research and development efforts, ensuring that its products are at the cutting edge of scientific advancement while remaining true to its dedication to clean and effective formulations.
In addition to supporting product innovation, the capital infusion will fuel strategic partnerships and further technological integrations with Signum Biosciences, a renowned biopharmaceutical company that specializes in the discovery and development of groundbreaking compounds and botanical extracts. With a robust in-house team of scientists and access to technology discovered by Dr. Jeffry Stock at Princeton University, Epicutis is set to accelerate its mission of developing novel ingredients that regulate cellular signaling and promote overall skin wellness. The raised funds will also enable the company to expand its market reach, enhance consumer experiences, and invest in sustainable practices that align with its clean beauty ethos. To learn more about Epicutis and its transformative approach to skincare, please visit www.epicutis.com. For additional insights into the pioneering work at Signum Biosciences, visit www.signumbiosciences.com.
